That is not at all clear.
The director-general met with manufacturers on April 14. I was part of that meeting. What we heard from manufacturers was a real issue around increasing manufacturing capacity, actually finding the facilities to manufacture the vaccines and then also finding the technical expertise to assist in the production, because it's a difficult and complicated process for developing and manufacturing these vaccines. It's not at all clear how quickly that could be ramped up. It's quite unfortunate, but that seems to be a real problem.